Servier, a French bio/pharmaceutical company, has agreed to acquire the muscular dystrophy business of Edgewise Therapeutics, a bio/pharmaceutical company focused on serious muscle disorders, for up to $2.65 billion ($1.55 billion upfront and $1.1 billion in milestone payments). 

The acquisition of Edgewise Therapeutics’ muscular dystrophy business includes its associated capabilities as well as sevasemten, an investigational orally administered myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced damage in individuals living with rare muscular dystrophy. Sevasemten is currently being investigated for Becker muscular dystrophy and is in Phase II development for treating Duchenne muscular dystrophy.  

The transaction has been approved by both companies’ respective governance bodies. The transaction is subject to regulatory clearance and customary closing conditions and is expected to close in the third quarter of 2026. 

Source: Servier